J H Schiller

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi request reprint Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe
    Joan Schiller
    University of Wisconsin Hospital, Room K4 538, 600 Highland Avenue, Madison, WI 53792, USA
    Lung Cancer 43:101-12. 2004
  2. ncbi request reprint Adjuvant systemic therapies in early-stage non-small-cell lung cancer
    Joan H Schiller
    Medical Oncology, University of Wisconsin Hospital and Clinics, Madison, USA
    Clin Lung Cancer 5:S29-35. 2003
  3. ncbi request reprint Small cell lung cancer: defining a role for emerging platinum drugs
    Joan H Schiller
    University of Wisconsin Hospital, Madison, 53792, USA
    Oncology 63:105-14. 2002
  4. ncbi request reprint Study design issues and early stage non-small cell lung cancer
    Joan H Schiller
    University of Wisconsin Comprehensive Cancer Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Clin Cancer Res 11:5030s-5032s. 2005
  5. ncbi request reprint Current standards of care in small-cell and non-small-cell lung cancer
    J H Schiller
    University of Wisconsin Hospital and Clinics, Madison, 53792, USA
    Oncology 61:3-13. 2001
  6. ncbi request reprint Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group
    J H Schiller
    University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    J Clin Oncol 19:2114-22. 2001
  7. ncbi request reprint Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy
    J H Schiller
    William S Middleton Veterans Administration Hospital and University of Wisconsin, Madison 53792, USA
    J Clin Oncol 19:448-57. 2001
  8. ncbi request reprint Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization
    J H Schiller
    William S Middleton Veterans Administration Hospital and University of Wisconsin Department of Medicine, Madison 53705, USA
    Clin Cancer Res 5:4287-94. 1999
  9. ncbi request reprint Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival
    J H Schiller
    Department of Human Oncology, University of Wisconsin, Madison, USA
    J Clin Oncol 14:1913-21. 1996
  10. ncbi request reprint Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial
    J H Schiller
    University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    J Clin Oncol 14:2345-52. 1996

Collaborators

Detail Information

Publications66

  1. ncbi request reprint Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe
    Joan Schiller
    University of Wisconsin Hospital, Room K4 538, 600 Highland Avenue, Madison, WI 53792, USA
    Lung Cancer 43:101-12. 2004
    ....
  2. ncbi request reprint Adjuvant systemic therapies in early-stage non-small-cell lung cancer
    Joan H Schiller
    Medical Oncology, University of Wisconsin Hospital and Clinics, Madison, USA
    Clin Lung Cancer 5:S29-35. 2003
    ..A combination of these new approaches and standard therapy for NSCLC may improve long-term survival in patients with lung cancer..
  3. ncbi request reprint Small cell lung cancer: defining a role for emerging platinum drugs
    Joan H Schiller
    University of Wisconsin Hospital, Madison, 53792, USA
    Oncology 63:105-14. 2002
    ..If the early promise shown by these compounds is confirmed in the clinic, they may offer a new approach to the treatment of SCLC, including recurrent disease for which limited treatment options are currently available...
  4. ncbi request reprint Study design issues and early stage non-small cell lung cancer
    Joan H Schiller
    University of Wisconsin Comprehensive Cancer Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Clin Cancer Res 11:5030s-5032s. 2005
    ..Education of health care professionals regarding the benefits of adjuvant therapies, to decrease a sense of nihilism and to increase referrals, and international collaborations may also be necessary to increase accrual...
  5. ncbi request reprint Current standards of care in small-cell and non-small-cell lung cancer
    J H Schiller
    University of Wisconsin Hospital and Clinics, Madison, 53792, USA
    Oncology 61:3-13. 2001
    ..This article reviews the current standards of care in SCLC and NSCLC, and introduces the potential role of newer agents given in combination with standard chemotherapy...
  6. ncbi request reprint Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group
    J H Schiller
    University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    J Clin Oncol 19:2114-22. 2001
    ..To determine the efficacy of topotecan in combination with standard chemotherapy in previously untreated patients with extensive-stage small-cell lung cancer (SCLC), the Eastern Cooperative Oncology Group (ECOG) conducted a phase III trial...
  7. ncbi request reprint Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy
    J H Schiller
    William S Middleton Veterans Administration Hospital and University of Wisconsin, Madison 53792, USA
    J Clin Oncol 19:448-57. 2001
    ..To determine the prognostic and predictive significance of p53 and K-ras mutations in patients with completely resected non-small-cell lung cancer (NSCLC)...
  8. ncbi request reprint Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization
    J H Schiller
    William S Middleton Veterans Administration Hospital and University of Wisconsin Department of Medicine, Madison 53705, USA
    Clin Cancer Res 5:4287-94. 1999
    ..These data demonstrate that the combination of squalamine and a platinum analog has significant preclinical antitumor activity against human lung cancer that is related to the anti-angiogenic effects of squalamine...
  9. ncbi request reprint Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival
    J H Schiller
    Department of Human Oncology, University of Wisconsin, Madison, USA
    J Clin Oncol 14:1913-21. 1996
    ....
  10. ncbi request reprint Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial
    J H Schiller
    University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    J Clin Oncol 14:2345-52. 1996
    ....
  11. ncbi request reprint Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
    K M Leu
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Lung Cancer 34:105-13. 2001
    ....
  12. ncbi request reprint Future role of topotecan in the treatment of lung cancer
    J H Schiller
    University of Wisconsin Hospital, Madison, 53792, USA
    Oncology 61:55-9. 2001
    ..Preliminary results of some of these trials are presented in this summary. The results of other clinical experience trials are eagerly anticipated...
  13. ncbi request reprint Loss of the tumorigenic phenotype with in vitro, but not in vivo, passaging of a novel series of human bronchial epithelial cell lines: possible role of an alpha 5/beta 1-integrin-fibronectin interaction
    J H Schiller
    William S Middleton Veterans Administration Hospital, Madison, Wisconsin 53705, USA
    Cancer Res 55:6215-21. 1995
    ....
  14. ncbi request reprint Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma
    D M Mahvi
    Department of Surgery, H4 726 Clinical Science Center, Madison, Wisconsin 53792, USA
    Hum Gene Ther 8:875-91. 1997
    ..Restaging of the patients' disease and long term toxicity evaluation will be performed at 3, 6, and 12 months and then yearly...
  15. ncbi request reprint Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2
    M E Eastman
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Cancer 91:806-14. 2001
    ..The risk of DRT appears to be higher than the risk reported for patients with similar devices but not given IL-2. Low dose warfarin did not prevent DRT when started after device placement...
  16. ncbi request reprint Phase I study of docetaxel and topotecan in patients with advanced malignancies
    Sarita Dubey
    Department of Medicine, Medical Oncology Section, University of Wisconsin Comprehensive Cancer Center, Madison, USA
    J Oncol Pharm Pract 11:131-8. 2005
    ..We designed a phase I study to evaluate the maximum tolerated dose of this combination and to assess the impact of pharmacokinetic interactions of the two drugs on toxicity...
  17. ncbi request reprint Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology and Dana Farber Partners Cancer Care, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Clin Cancer Res 11:4981s-4983s. 2005
  18. ncbi request reprint Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer
    Tien Hoang
    Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA
    J Thorac Oncol 1:218-25. 2006
    ..The study was designed to evaluate the safety and efficacy of exisulind, a selective apoptotic antineoplastic drug, in combination with gemcitabine as second-line therapy in patients with progressing advanced non-small cell lung cancer...
  19. ncbi request reprint Angiogenesis inhibitors in the treatment of lung cancer
    Sophie Sun
    Division of Hematology and Oncology, University of Texas Southwestern, Dallas 75390 8852, USA
    Crit Rev Oncol Hematol 62:93-104. 2007
    ..Recent clinical trials have yielded promising results. This article will review angiogenesis inhibitors targeting the VEGF pathway which are currently being developed for the treatment of lung cancer...
  20. pmc Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States
    Lung Cancer 56:97-103. 2007
    ..This is the first comprehensive study of this transcription factor in patients with NSCLC...
  21. ncbi request reprint Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...
  22. ncbi request reprint Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
    Michael P Fanucchi
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    J Clin Oncol 24:5025-33. 2006
    ..To evaluate the efficacy and toxicity of bortezomib +/- docetaxel as second-line therapy in patients with relapsed or refractory advanced non-small-cell lung cancer (NSCLC)...
  23. ncbi request reprint Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial
    Heather A Wakelee
    Stanford Cancer Center, CA 94305 5826, USA
    Clin Lung Cancer 8:18-21. 2006
    ..Because of the recent update, this trial will now limit patients with stage IB disease to those with larger tumors (>or= 4 cm) and will likely include only cisplatin-based regimens...
  24. ncbi request reprint PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2
    Kathy S Albain
    Loyola University, Chicago Medical Center, Maywood, IL 60153, USA
    Clin Lung Cancer 7:417-9. 2006
  25. ncbi request reprint Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990
    Heather A Wakelee
    Department of Medicine, Division of Medical Oncology, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
    Cancer 106:2208-17. 2006
    ....
  26. ncbi request reprint Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
    Heather A Wakelee
    Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305 5826, USA
    J Thorac Oncol 1:441-6. 2006
    ..E1594 randomized patients with advanced NSCLC to one of four platinum doublets and found that all four regimens had comparable efficacy...
  27. doi request reprint Assessment of guilt and shame in patients with non-small-cell lung cancer compared with patients with breast and prostate cancer
    Noelle K Loconte
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Clin Lung Cancer 9:171-8. 2008
    ..This study was designed to determine the levels of guilt and shame among patients with non-small-cell lung cancer (NSCLC) compared with breast and prostate cancer...
  28. doi request reprint Noninvasive monitoring of tumors
    Joan H Schiller
    N Engl J Med 359:418-20. 2008
  29. doi request reprint Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study
    Afshin Dowlati
    University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio 44016, USA
    Clin Cancer Res 14:1407-12. 2008
    ....
  30. doi request reprint Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Clin Oncol 26:60-5. 2008
    ..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients...
  31. ncbi request reprint A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
    Kishan J Pandya
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    J Thorac Oncol 2:1036-41. 2007
    ..To study the progression-free survival (PFS) and toxicity with 25- or 250-mg doses of temsirolimus (CCI-779) after induction chemotherapy in patients with extensive small-cell lung cancer...
  32. ncbi request reprint Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
    ..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)...
  33. doi request reprint Addressing the current challenges of non-small-cell lung cancer clinical trial accrual
    Walter J Curran
    Department of Radiation Oncology, The Emory Clinic, Atlanta, GA 30322, USA
    Clin Lung Cancer 9:222-6. 2008
    ....
  34. ncbi request reprint Lung cancer in never smokers--a different disease
    Sophie Sun
    Division of Haematology and Oncology and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Nat Rev Cancer 7:778-90. 2007
    ..This Review summarizes our current knowledge of this unique and poorly understood disease...
  35. ncbi request reprint Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer
    Timothy R Wassenaar
    University of Wisconsin School of Medicine and Public Health, Department of Medicine, Madison, Wisconsin, USA
    J Thorac Oncol 2:722-8. 2007
    ..We conducted a survey of primary care physicians to determine whether treatment and referral patterns of breast cancer patients differed from those of lung cancer patients...
  36. ncbi request reprint Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis
    Andrea Ardizzoni
    Division of Medical Oncology, University Hospital, Via Gramsci 14, 43100 Parma, Italy
    J Natl Cancer Inst 99:847-57. 2007
    ..Because the efficacy of carboplatin and cisplatin in the treatment of advanced non-small-cell lung cancer (NSCLC) has not been proven to be equivalent, an individual patient data meta-analysis comparing the two treatments was performed...
  37. ncbi request reprint Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab
    Sarita Dubey
    University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA
    Oncologist 10:282-91. 2005
    ..All three drugs are approved for different tumor types, and studies defining their role in NSCLC are under way...
  38. ncbi request reprint Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Department of Oncology, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
    J Clin Oncol 22:777-84. 2004
    ..Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability...
  39. ncbi request reprint Chemotherapy for advanced non-small cell lung cancer
    Sarita Dubey
    Department of Medicine, University of Wisconsin, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
    Hematol Oncol Clin North Am 18:101-14. 2004
    ..In second-line setting, docetaxel is the agent that has been extensively studied and approved. Furthermore, molecularly targeted therapy holds a promising future and is discussed in articles elsewhere in this issue...
  40. ncbi request reprint Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 22:785-94. 2004
    ..This phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC...
  41. ncbi request reprint New directions for ZD1839 in the treatment of solid tumors
    Joan H Schiller
    Section of Medical Oncology, Department of Medicine, University of Wisconsin Medical School, Comprehensive Cancer Center, Madison, WI 53792 6164, USA
    Semin Oncol 30:49-55. 2003
    ..Chemoprevention trials have been initiated to assess the potential of ZD1839 to delay or prevent the progression of common solid tumors such as non-small cell lung cancer...
  42. ncbi request reprint Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
    Mark G Kris
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY 10021, USA
    JAMA 290:2149-58. 2003
    ....
  43. ncbi request reprint A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology and Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 9:4108-15. 2003
    ....
  44. ncbi request reprint Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
    Tien Hoang
    Room K4 538, Clinical Science Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Lung Cancer 42:97-102. 2003
    ..Eligibility criteria included prior treatment with only one chemotherapy regimen and Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients with brain metastases were eligible...
  45. ncbi request reprint Platin or no platin? That is the question
    Joan H Schiller
    J Clin Oncol 21:3009-10. 2003
  46. ncbi request reprint Novel therapies for the treatment of non-small cell lung cancer
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Cancer Chemother Biol Response Modif 20:763-86. 2002
    ..In addition, we need new techniques to assist those who are already addicted to escape from tobacco's death grip. Sadly, most users of tobacco still fail to recognize the dangers of their habit. This needs to change!..
  47. ncbi request reprint Novel agents in the treatment of lung cancer: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 10:4199s-4204s. 2004
  48. ncbi request reprint Clinical trial design issues in the era of targeted therapies
    Joan H Schiller
    University of Wisconsin Madison, Wisconsin, USA
    Clin Cancer Res 10:4281s-4282s. 2004
    ..Although our lack of effective therapies mandates the development of new, molecularly targeted therapies, a number of issues in the design of clinical trials and their end points remain to be considered...
  49. ncbi request reprint Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Joan H Schiller
    University of Wisconsin Hospital and Clinics, Madison, USA
    N Engl J Med 346:92-8. 2002
    ..We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer...
  50. ncbi request reprint Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial
    David Cella
    Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Ste 100, Evanston, IL 60201, USA
    J Clin Oncol 23:2946-54. 2005
    ..Among these NSCLC patients treated with gefitinib, symptom improvement was complementary to and, for most patients, preceded evidence of radiographic regression...
  51. ncbi request reprint Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data
    Tien Hoang
    University of Wisconsin Medical School, 600 Highland Ave, K4 562, Madison, WI, USA
    J Clin Oncol 23:175-83. 2005
    ....
  52. ncbi request reprint Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors
    Diane R Mould
    Projections Research Inc, 535 Springview Lane, Phoenixville, PA 19460, USA
    Clin Pharmacol Ther 71:334-48. 2002
    ..Our objective was to describe the pharmacokinetics and pharmacodynamics of topotecan in patients...
  53. ncbi request reprint Systemic treatment of advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Drugs Today (Barc) 40:697-710. 2004
    ....
  54. ncbi request reprint Novel therapies for lung cancer
    Tien Hoang
    Department of Medicine, Medical Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
    Surg Oncol 11:229-41. 2002
    ....
  55. ncbi request reprint Can current treatments for advanced non-small-cell lung cancer be improved?
    Athanassios Argiris
    JAMA 292:499-500. 2004
  56. ncbi request reprint Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease
    Steven M Keller
    Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY 10467, USA
    J Thorac Cardiovasc Surg 128:130-7. 2004
    ....
  57. ncbi request reprint Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy
    Tien Hoang
    Department of Medicine, University of Wisconsin Medical School, Madison 53792, USA
    Expert Rev Anticancer Ther 2:393-401. 2002
    ..These novel agents target molecular pathways specifically found in cancer cells, thus maximizing the antitumor effect while minimizing toxicities on normal cells...
  58. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors
    James P Thomas
    Department of Medicine, Section of Medical Oncology and University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, 53792, USA
    J Clin Oncol 21:223-31. 2003
    ..A phase I trial of recombinant human endostatin was designed to evaluate toxicity and explore biologic effectiveness in patients with refractory solid tumors...
  59. doi request reprint Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000)
    Joan H Schiller
    University of Texas Southwestern, Dallas, Texas 75390 8852, USA
    Cancer Invest 26:81-95. 2008
    ..Skin rash is the most common toxicity, but is severe (Grade 3) in < 1 percent. This article describes preclinical and clinical development of matuzumab...
  60. ncbi request reprint EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer
    Sarita Dubey
    University of California, San Francisco, San Francisco, California 94115, USA
    J Thorac Oncol 1:406-12. 2006
    ..The authors hypothesized that a shorter length of tumor SSR would be associated with poorer survival in patients with non-small cell lung cancer (NSCLC)...
  61. ncbi request reprint Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer
    Sarita Dubey
    University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    J Support Oncol 3:149-54. 2005
    ..Better communication between physician and patient about the likelihood of side effects may reduce chemotherapy-related stress for patients...
  62. ncbi request reprint Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs
    Gregory A Otterson
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
    Clin Cancer Res 13:1246-52. 2007
    ..To evaluate the toxicity profile of inhalational doxorubicin in patients with malignant disease in the lung...
  63. pmc Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients
    David M King
    University of Wisconsin, Madison, WI 53792, USA
    J Clin Oncol 22:4463-73. 2004
    ..To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma...
  64. ncbi request reprint Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer
    Heather A Wakelee
    Oncology Division, Stanford University School of Medicine, CA, USA
    Clin Lung Cancer 7:S31-8. 2005
    ..We present phase I data (and phase II/III data when available) of these compounds and discuss their potential development in the treatment of lung cancer...
  65. ncbi request reprint Using liquid crystals to report membrane proteins captured by affinity microcontact printing from cell lysates and membrane extracts
    Chang Hyun Jang
    Department of Chemical and Biological Engineering, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Am Chem Soc 127:8912-3. 2005
    ..Detection of epidermal growth factor receptor, a transmembrane glycoprotein, is demonstrated...
  66. pmc New molecularly targeted therapies for lung cancer
    Sophie Sun
    Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Clin Invest 117:2740-50. 2007
    ..This article will review the important clinical implications of these advances, with a focus on new molecularly targeted therapies currently in development...